In recent years, several classes of small regulatory RNAs have been identified in a range of tissues and in many species. These small RNAs include the microRNAs (miRNAs), which are 18-25 nucleotides long and are generated by a series of cleavage events from long, polymerase II-transcribed RNA 1 . miRNAs guide the RNA-induced silencing complex (RISC) to mRNAs that have a target sequence complementary to that of the miRNA (FIG. 1a) . The interaction between the miRNA and the target does not need to be completely complementary: the most important pairing involves nucleotides 2-7 of the miRNA, the so-called seed sequence. With some rare exceptions 2 , an mRNA that is targeted by RISC will be translationally silenced or destabilized and degraded 3 . In either case, the outcome is a decrease in protein production, with consequences for biological function that depend on which mRNA is targeted. In the nervous system, these consequences include effects on neurogenesis [4] [5] [6] , dendritic outgrowth 7, 8 and dendritic spine formation 9, 10 . Alterations in the tuning of protein production are linked to many neurodegenerative diseases. For example, one extra copy of the normal α-synuclein gene is sufficient to cause Parkinson's disease (PD) in one family 11 . Similarly, duplication of APP, which encodes the β-amyloid precursor 12, 13 , or mutations in its regulatory region that increase its transcriptional activity 14, 15 can lead to early-onset Alzheimer's disease (AD) or an increased risk of AD, respectively. These examples highlight what is thought to be a central mechanism in neurodegenerative diseases: increased accumulation of toxic proteins leads to neuronal dysfunction. miRNAs might modulate the accumulation of these toxic proteins by regulating either their mRNAs or the mRNAs of proteins that affect their expression (FIG. 1b) . Furthermore, miRNAs might contribute to the pathogenesis of neurodegenerative disease downstream of the accumulation of toxic proteins by altering the expression of other proteins that promote or inhibit cell survival. Here, we discuss our current understanding of the contributions of miRNAs in neurodegenerative disease (TABLE 1) and consider how recent advances in technology could be implemented to advance the field.
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miRNAs support neuronal survival Neural cell death is the defining feature of all neurodegenerative diseases and is the underlying cause of many functional deficits. Clarifying the pathways that promote and prevent cell death in the nervous system is therefore essential to understand disease pathology and to devise effective treatment strategies. Neuronal survival is supported by various proteins, including those that provide trophic support, for example brainderived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF) and nerve growth factor (NGF). Pro-survival proteins, such as BCL-2 and BCL-X L , also inhibit cell death programmes. miRNAs might regulate neuronal survival by inhibiting negative regulators of these pro-survival factors or by regulating the pro-survival proteins themselves in response to survival cues, such as neuronal activity.
A blunt but useful approach to define the roles of miRNAs in any process, including neuronal survival, is to disable the miRNA biogenesis pathway. In particular, this strategy has been used to investigate the role of miRNAs in neuronal survival during development. One of the first such studies used a cerebellar Purkinje cell-specific knockout of Dicer, an enzyme that is essential for the generation of miRNAs 16 . This resulted in the depletion of all mature miRNAs in these cells and was associated with a progressive neurodegenerative phenotype that is characterized by ataxia (the loss of motor control) and Purkinje cell degeneration 17 . In another study, the dopamine receptor 1-Cre (Dr1-Cre; Dr1 is also known as Drd1a) driver was used to delete the Dicer gene in DR1-expressing neurons of the striatum 18 . These mutants had substantially lower brain masses than their wild-type littermates, a phenotype that could be suggestive of neurodegeneration. However, there were signs of reactive gliosis -a condition that is associated with neuronal cell death -but no clear signs of cell death in the adult Dr1-Cre mutants. The authors of the study therefore suggested that the decreased brain mass might have resulted from a combination of neuronal death during development and hypertrophy of Dicer-null neurons.
Similar observations were made in Dicer mutants generated using the calmodulin kinase IIα-Cre (Camk2a-Cre) driver, which inactivates Dicer in several regions, including the forebrain 19 . These mice had substantially smaller brains than control mice, which was shown to be due, in part, to increased cell death in the early postnatal period. The complexity of the dendritic architecture of CA1 hippocampal neurons was also dramatically reduced in Camk2a-Cre knockouts, although it is unclear whether this was a degenerative or developmental effect. For both the Dr1-Cre and Camk2a-Cre Dicer ablations, developmental neuronal death seemed to contribute to the gross reduction in brain mass, an effect that is consistent with the roles of miRNAs in neuronal development. As with most AAAAAA 7me G AAAAAA 7me G Nature Reviews | Neuroscience developmental processes, neuronal number is controlled by a balance of cell division and programmed cell death. Therefore, it is difficult to say whether the gross phenotypes observed in the Dr1-Cre and Camk2a-Cre Dicer mutants are due to cell death, the absence of cell proliferation or both.
Deletion of Dicer in mature mouse olfactory neurons had little effect on their survival or function, although the ablation of Dicer in immature olfactory neurons resulted in failed differentiation 20 . The Emx1-Cre line 5 has been used to ablate Dicer from the developing mouse cortex at embryonic day 9.5 (e9.5), when cortical neurogenesis is initiated. As in the olfactory system, cortical progenitor pools seem to be unaffected by the removal of miRNAs. Furthermore, the first wave of neurogenesis seems to occur normally, but massive numbers of apoptotic cells are observed by e12.5 in the neuronal layer of the developing cortex.
Although these experiments are complicated by the long half-lives of miRNAs and Dicer, these results seem to suggest that miRNAs are not required in neural progenitors but are required for the specification and survival of some types of mature neurons. Whether key individual miRNA-target pairs or broad regulation of the neuronal proteome are crucial factors for neuronal survival in these knockout models remains to be determined. Together, these studies have established that miRNAs can promote the survival of neurons, but the precise mechanism by which this occurs will require further research.
The discovery of a common single nucleotide polymorphism (SNP) in the 3′ untranslated region (uTR) of the granulin (GRN; also known as progranulin) gene provided a direct connection between a pro-survival gene and a miRNA in neurodegenerative disease. GRN is a secreted protein with anti-apoptotic properties that have been described outside of the CNS 21 . Notably, mutations in GRN are linked to familial forms of frontotemporal lobe dementia (FTLD) [22] [23] [24] . The 3′ uTR SNP was found to associate with a subtype of FTLD 25 and to enhance the ability of the human-specific miRNA miR-659 to bind to GRN mRNA and regulate its translation. GRN is reduced in tissues in patients with the disease-associated SNP. using quantitative reverse transcription PCR (qRT-PCR) it was found that mir-659 is expressed in the brain. However, the relative abundance of miR-659 in brain tissue of patients with FTLD is unknown, and therefore the relevance of this particular miRNA in the pathogenesis of FTLD is currently unclear. Nevertheless, this study could provide the basis for further inquiry into the role of miRNA regulation in FTLD.
miRNAs alter protein accumulation. A common theme among many neurodegenerative conditions is the accumulation of proteins that are toxic to neurons. miRNAs could act at many stages in the production of toxic proteins, and changes in their activity at these stages could therefore be important for neurodegenerative disease pathology. most directly, for example, miRNAmediated regulation of the mRNA of a toxic protein could be lost. Perhaps equally as importantly, miRNA-mediated regulation of proteins that are involved in the production or degradation of toxic proteins could also be lost.
A recent study found that a small number of miRNAs have modestly altered expression levels in patients with AD 26 . Armed with this data, the authors used in silico predictions of miRNA targets to determine the miRNAs that were worth pursuing
. Among the downregulated miRNAs, the miR-29 family can regulate the 3′ uTR of β-site APPcleaving enzyme 1 (BACE1) in a luciferase reporter assay. BACe1 is central to the production of the toxic amyloid-β peptide, the principal component of the plaques that characterize AD. Indeed, the authors demonstrated a significant correlation between lower expression of mir-29a or mir-29b and higher expression of BACE1 in brain tissue. These miRNAs are thought to be ubiquitously expressed in neurons and astroglia, suggesting that specific reductions in their expression are not a secondary consequence of the death of specific neuronal a | MicroRNAs (miRNAs; blue) bind their target mRNAs through sequences in the 3′ untranslated region of the mRNA. miRNAs require only a short span of sequence complementarity at their 5′ end to guide the RNA-induced silencing complex (RIsC) to the mRNA, which promotes either translational repression or mRNA decay. Although many mechanisms for RNA silencing have been proposed, the prevailing view in the field is that RIsC-mediated translational control occurs at the step of translation initiation. RIsC-induced mRNA decay is thought to occur by deadenylation of the poly(A) tail followed by mRNA destruction. b | Proposed mechanisms by which miRNAs could influence neurodegeneration. Alterations in miRNA function could result from changes in their expression through genetic or epigenetic changes. This would result in either the reduction or the absence of the miRNA. Alternatively, mutation of a miRNA-binding site in the 3′ untranslated region of a target mRNA can disrupt miRNAmediated repression. miRNAs have been shown to regulate proteins that are involved in the production of toxic proteins as well as toxic proteins themselves. Thus, reductions in miRNA activity might lead to the increased accumulation of toxic proteins, which, in turn, could cause neuronal death or affect the expression of unidentified pro-survival miRNAs. miR-9 might have pro-survival functions through its interaction with Re1 silencing transcription factor (ResT) and its co-repressor CoResT (also known as RCoR1) 34 .
populations. The transfection of mir-29a or mir-29b in HeK293 cells that express APP, from which amyloid-β peptide is formed, significantly reduced the production of the amyloid-β peptide. This suggests that these miRNAs can significantly modulate BACE1 and consequently the production of the toxic amyloid-β peptide. Currently, there is no evidence to indicate that genetic polymorphisms in mir-29a and mir-29b, or the 3′ uTRs of APP or BACE1, contribute to AD, which suggests that the interaction between BACE1 and these two miRNAs might not be causative in familial forms of AD 27 . Protein accumulation in neurodegenerative disease could also be affected by polymorphisms in 3′ uTRs, as these could either add or eliminate miRNA target sites in mRNAs. For example, a recent study of risk factors for PD identified a point mutation in the 3′ uTR of fibroblast growth factor 20 (FGF20) that disrupts a miR-433-binding site 28 . FGFs regulate α-synuclein expression in vitro 29 , and increases in α-synuclein expression can contribute to the development of PD 30 . Polymorphisms in the 3′ uTR can increase the expression of FGF20 and alter the expression of α-synuclein in cell culture. However, the low level of miR-433 detected in the brain might mean that it is unlikely that this specific interaction has any relevance to PD pathology. Nonetheless, it is possible that mir-433 is expressed in a minor cell population that has relevance for PD. To address this possibility, future studies could use in situ hybridization to determine whether dopamine neurons or neighbouring cells are enriched in mir-433 expression. This could lend credence to the hypothesis that a miRNA with a low expression level could affect α-synuclein expression through FGF signalling in disease-relevant cell types. However, it is also worth noting that a recent study could not reproduce any association between PD and FGF20 (REF. 31 ).
An early observation that suggested that miRNAs might be involved in neurodegenerative disease was made in a Drosophila melanogaster model of spinal cerebellar ataxia 32 . Neurodegeneration caused by overexpression of a polyglutamine-expanded human ataxin in the D. melanogaster eye was enhanced by a heterozygous mutation in Dicer1. Conversely, overexpression of the bantam miRNA suppressed ataxin-induced neurodegeneration, although the mechanism by which this suppression occurred remains unclear. Overexpression of polyglutamine-expanded human ataxin is also toxic in HeK293 cells; in this model, as in the fly eye, ataxin toxicity was enhanced by knockdown of Dicer, which suggests that the enhancement is a widespread phenomenon. Although this study did not produce evidence that miRNAs directly regulate ataxin expression, a related study showed that a variety of miRNAs are capable of regulating the human ataxin mRNA in HeK293 cells 33 . Importantly, the authors showed that these miRNAs are expressed in Purkinje cells, one of the main target cell types of the disease. Ataxin-induced toxicity was accentuated in HeK293 cells by either the knockdown of these miRNAs or the deletion of the miRNA binding sites in the 3′ uTR of the ataxin mRNA. experiments in Purkinje cells and in vivo will be required to further determine the importance of these miRNA-ataxin interactions in the brain.
miRNAs downstream of toxic proteins.
Although the accumulation of toxic proteins is thought to be the cause of many neurodegenerative conditions, the mechanism by which the toxic proteins cause cell death remains controversial. One possible mechanism is by interfering with miRNA-mediated regulation of pro-survival proteins.
Profiling of miRNA expression in tissues from patients with Huntington's disease (HD) showed significant decreases in mir-9 and mir-9* expression as the disease progresses 34 . Alterations in mir-9 and mir-9* can affect the expression of the Re1 silencing transcription factor (ReST) and its corepressor CoReST (also known as RCOR1). This is important because upregulation of the ReST repressor complex can have deleterious effects on neuronal gene expression, repressing pro-survival genes (such as BDNF) that might contribute to HD pathogenesis 35 . These results, together with those of other recently published HD studies, suggest that a reciprocal transcription-translation circuit exists through which ReST can in turn repress mir-9 transcription. The activity of ReST is increased by mutant huntingtin protein 35 , which causes HD. Previous studies have shown that ReST binds to DNA upstream of neuronally expressed miRNAs, including the loci from which miR-9, miR-124 and miR-132 are transcribed 36 . The interaction between ReST and the upstream regions of miRNA coding sequences was confirmed by studying the impact of ReST-mediated transcription in HD 37 . The group behind this study also investigated the expression of miRNAs by looking at post-mortem brains of patients with HD. Although many of the overall conclusions of the two studies were similar, there was little similarity between findings on the expression of miRNAs in patients with HD-affected brains. For instance, by looking at post-mortem samples, REF. 37 reported a significant decline in mir-132 expression in HD-affected cortex, whereas REF. 34 noted a significant increase in mir-132 expression in late-stage HD-affected brains. This could be a consequence of either differing methods of measuring miRNA expression levels or the noted heterogeneity of gene expression profiles in HD brains, or it might indicate that the small sample size of each study was insufficient to power the analysis of the data.
Profiling of post-mortem tissue also identified reduced miR-133b in the midbrain of patients with PD 16 . A trivial explanation for this reduction is that miR-133b is enriched in the dopamine neurons that are lost during disease progression. This seems to be the case, as miR-133b is enriched in the midbrain and is depleted in mouse models that are deficient in dopamine neurons, which suggests that the loss of miR-133b is downstream of the accumulation of toxic protein and dopamine neuron death. However, the group also uncovered a developmental feedback loop through which pituitary homeobox 3 (PITX3), a transcription factor that has a key role in dopamine neuron development, regulates mir-133b transcription, and miR-133b in turn represses PITX3 synthesis. Whether this regulatory loop contributes to the survival of midbrain dopamine neurons or whether miR-133b regulates other important factors in dopamine neurons remains to be determined.
Future efforts
The exploitation of miRNA biology to understand and treat neurological disease presents a novel and exciting opportunity. How will our understanding of miRNA in neurodegeneration intersect with therapeutics? miRNA-based interventions that enhance the endogenous neuroregenerative or neuroprotective capacity of the CNS are attractive, but at present the targeting of specific miRNAs to directly treat neurodegenerative diseases is faced with many challenges. First, we need to understand the extent of protein regulation by miRNAs. A single miRNA might regulate the expression of a few proteins or a large network of proteins. Second, the cellular feedback loops and mechanisms of regulation of miRNA expression are not yet known. There is also a paucity of validated miRNA targets and the delivery of miRNA reagents to the brain is currently hampered by difficulties. However, these are resolvable challenges. The delivery of oligonucleotides, ribozymes, small interfering RNA and mRNA using viral and non-viral methods for gene therapy is currently the focus of extensive efforts in medical research and, although effective delivery to neural tissues has yet to be realized, significant advances have been achieved through nanotechnology 38 . Oligonucleotidebased miRNA therapy has the advantage of being transient, whereas viral or transgenic modification presents a variety of risks, including viral-induced inflammation and oncogenesis.
Despite these challenges, there might come a time when the regulation of the expression or activity of miRNAs is possible and has clear therapeutic benefits. One possible strategy would be to enhance the expression of miRNAs that target toxic proteins by providing either synthetic miRNA or virally expressed miRNA. Inhibiting miRNA-mediated repression of a neuroprotective mRNA might also represent an important therapeutic approach. using miRNA in an ex vivo setting to expand cultures or to prompt stem cells to adopt appropriate fates also holds promise for models of neurodegenerative disease or replacement therapies. All of these approaches will require significant advances in delivery technology to be successful. In addition, a precise understanding of miRNA-target relationships, including the cells in which each is expressed, is an absolute requirement for therapeutic effectiveness. To arrive at this point, we must improve how we investigate miRNA expression and function.
One such improvement would be the use of cell type-specific miRNA expression profiles. Although there is clear value in obtaining expression profiles of diseased tissues, knowing where and when the miRNAs are expressed also has clear and important implications for disease mechanisms and possible therapeutic intervention. Recent advances in in situ hybridization techniques might rapidly improve this caveat of miRNA profiling studies, which has been largely ignored to date 39 . Similarly, very few profiling experiments have begun to consider the differences in miRNA expression in neurons and glia. This is an obvious and important question when considering the mechanism of miRNA action.
Currently, our understanding of miRNA action suggests that they are stoichiometric inhibitors of mRNA translation. Therefore, only the most abundant miRNAs in a given tissue or cell type should be considered relevant to the biology of the tissue or cell. This further emphasizes the importance of the localization of miRNAs in specific cell types when identifying relevant miRNAs in neurodegenerative conditions. unbiased methodologies for miRNA target identification are also required. In silico methods for target identification are constantly improving (BOX 1) and, although already much improved, experimental methods for understanding the effect of changes in miRNA expression on the proteome are still emerging and will be essential tools. A recent study might point the way towards resolving this question 40 : by using HITS-CLIP (high throughput sequencing coupled with crosslinking immunoprecipitation) of RNA that is bound by RISC, both the miRNAs that are expressed in the brain and their likely mRNA targets could be identified. This represents an important leap forward in experimental miRNA target identification but does not resolve questions regarding cell type-specific miRNA expression. These technical advances should yield important details that will forward our understanding of the neural miRNA system in health and disease.
Box 1 | RNA target prediction programmes
A microRNA (miRNA) requires only a few base pair interactions to effectively silence a target mRNA. The most important region for interaction is the seed sequence (nucleotides 2-7 of the miRNA). A sequence of this length will occur with high frequency in the genome by chance alone, and therefore the prediction of functional miRNA target sites is challenging, even just within 3′ untranslated regions. Most target prediction programmes identify hundreds of potential targets for any given miRNA, but this might lead to user bias as it is likely that there will be a gene of interest within the list generated. This is particularly true for heavily studied genes with long and well annotated 3′ untranslated regions. Most successful target prediction algorithms rely on evolutionary conservation to identify hexanucleotide (or longer) seed region homologies that might indicate functional homology. This obviously precludes clade-specific target sites that might have important functional roles. Two recent studies of miRNA mutants were used to investigate the impact of the loss of a single miRNA on a proteome-wide level 41, 42 . They agreed that the most comprehensive and accurate prediction programmes are currently TargetScan and PicTar. Diana-microT has also been favourably evaluated. However, despite the relatively good performance of TargetScan and PicTar, two-thirds of their predicted targets were not affected by the absence of the miRNA 41 (see REF. 43 for a review).
